🇺🇸 FDA
Pipeline program

Curosurf, 240 mg/3 ml, suspensão para instilação endotraqueobrônquica

Phase 2 small_molecule active

Quick answer

Curosurf, 240 mg/3 ml, suspensão para instilação endotraqueobrônquica for Premature infants with Respiratory Distress Syndrome (RDS) is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Premature infants with Respiratory Distress Syndrome (RDS)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials